Table 2.
PFS With the Bayesian Hierarchical Model in Part 2
| Sarcoma Type | Ontuxizumab at 8.0 mg/kg + G/D | Placebo + G/D |
|---|---|---|
| Liposarcoma | ||
| No. | 30 | 15 |
| PFS observed, median, wk | 14.6 | 24.1 |
| Hazard ratio (95% CI) | 1.12 (0.69‐1.89) | |
| OS observed, median, wk | 58.5 | 54.4 |
| Hazard ratio (95% CI) | 1.1 (0.56‐1.87) | |
| BOR (% with response) | 20/30 (67) | 12/15 (80) |
| P | .236 | |
| Leiomyosarcoma | ||
| No. | 41 | 21 |
| PFS observed, median, wk | 18.3 | 24.0 |
| Hazard ratio (95% CI) | 1.08 (0.68‐1.61) | |
| OS observed, median, wk | 64.6 | 69.1 |
| Hazard ratio (95% CI) | 1.3 (0.74‐2.28) | |
| BOR (% with response) | 27/41 (66) | 16/21 (76) |
| P | .551 | |
| UPS | ||
| No. | 30 | 15 |
| PFS observed, median, wk | 10.3 | 33.6 |
| Hazard ratio (95% CI) | 1.23 (0.73‐2.09) | |
| OS observed, median, wk | 54.1 | 55.3 |
| Hazard ratio (95% CI) | 1.2 (0.68‐2.00) | |
| BOR (% with response) | 16/30 (53) | 11/15 (73) |
| P | .174 | |
| Other | ||
| No. | 38 | 19 |
| PFS observed, median, wk | 10.3 | 6.7 |
| Hazard ratio (95% CI) | 1.01 (0.60‐1.54) | |
| OS observed, median, wk | 56.6 | 57.1 |
| Hazard ratio (95% CI) | 1.1 (0.63‐1.70) | |
| BOR (% with response) | 24/38 (63) | 8/19 (42) |
| P | .389 | |
Abbreviations: BOR, best overall response (stable disease, partial response, or complete response); CI, confidence interval; G/D, gemcitabine and docetaxel; OS, overall survival; PFS, progression‐free survival; UPS, undifferentiated pleomorphic sarcoma.